Open access · CC-BY
via OpenAlex
Role of Cellular Senescence in Parkinson’s Disease: Potential for Disease-Modification Through Senotherapy
David J. Rademacher, Jacob E. Exline, Eileen M. Foecking
Biomedicines · 2025 · ▲ 5 citations
Cellular senescence
Altered intercellular communication
Chronic inflammation
Senolytics
Cell culture / in vitro
Non-human primate
Human
In vitro
Review
Abstract
Parkinson's disease (PD) is an aging-related neurodegenerative disease characterized by a progressive loss of dopamine (DA)-secreting neurons in the substantia nigra. Most of the currently available treatments attempt to alleviate the disease symptoms by increasing DA transmission in the brain and are associated with unpleasant side effects. Since there are no treatments that modify the course of PD or regenerate DA neurons, identifying therapeutic strategies that slow, stop, or reverse cell death in PD is of critical importance. Here, factors that confer vulnerability of substantia nigra DA neurons to cell death and the primary mechanisms of PD pathogenesis, including cellular senescence(definition), a cellular stress response that elicits a stable cell cycle arrest in mitotic cells and profound phenotypic changes including the implementation of a pro-inflammatory secretome, are reviewed. Additionally, a discussion of the characteristics, mechanisms, and markers of cellular senescence and the development of approaches to target senescent cells, referred to as senotherapeutics, is included. Although the senotherapeutics curcumin, fisetin, GSK-650394, and astragaloside IV had disease-modifying effects in in vitro and in vivo models of PD, the potential long-term side effects of these compounds remain unclear. It remains to be elucidated whether their beneficial effects will translate to non-human primate models and/or human PD patients. The enhanced selectivity, safety, and/or efficacy of next generation senotherapeutic strategies including senolytic peptides, senoreverters, proteolysis-targeting chimeras, pro-drugs, immunotherapy, and nanoparticles will also be reviewed. Although these next generation senotherapeutics may have advantages, none have been tried in models of PD.
◌ CITATION ONLY
Full text is not openly licensed for redistribution here. Read it at the source:
Provenance
- Source
- OpenAlex
- DOI
- 10.3390/biomedicines13061400
- Canonical
- link ↗
- Fetched
- 2026-09-02 MST
Cite this
APA
Rademacher, D.J., Exline, J.E., & Foecking, E.M. (2025). Role of Cellular Senescence in Parkinson’s Disease: Potential for Disease-Modification Through Senotherapy. <em>Biomedicines</em>. https://doi.org/10.3390/biomedicines13061400
Vancouver
Rademacher DJ, Exline JE, Foecking EM. Role of Cellular Senescence in Parkinson’s Disease: Potential for Disease-Modification Through Senotherapy. Biomedicines. 2025. doi:10.3390/biomedicines13061400.
BibTeX
@article{david2025Roleof,
title = {Role of Cellular Senescence in Parkinson’s Disease: Potential for Disease-Modification Through Senotherapy},
author = {David J. Rademacher and Jacob E. Exline and Eileen M. Foecking},
journal = {Biomedicines},
year = {2025},
doi = {10.3390/biomedicines13061400},
}
Research neighborhood
References, citing works, and semantically nearest findings. Click a node to open it.
Related findings
International Journal of Veterinary Sciences and Animal Husbandry 2026
Open access · OA
Senotherapeutics: emerging pharmacological strategies for targeting cellular senescence
Genetics and Molecular Research 2026
Open access · CC-BY
CELLULAR SENESCENCE: MOLECULAR MECHANISMS AND SENOLYTIC AND SENOMORPHIC STRATEGIES
Frontiers in immunology 2026
Open access · OA
Cellular senescence in multiple sclerosis: hallmarks, immunosenescence, and therapeutic implications.
Frontiers in Immunology 2026
Open access · CC-BY
Cellular senescence in multiple sclerosis: hallmarks, immunosenescence, and therapeutic implications
Journal of Bone and Mineral Research 2016
Preprint · OA
Identification of Senescent Cells in the Bone Microenvironment
Advances in Translational Research 2026
Open access · CC-BY